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Summary
Objective: Enhanced extracellular levels of adenosine have been shown to inhibit experimentally induced cartilage degradation. The
objective of this study was to investigate the role of adenosine and A2 adenosine receptors in regulating cartilage homeostasis in the absence
of inflammatory stimuli.
Methods: Cartilage explants were exposed to adenosine deaminase (ADA) to deplete extracellular adenosine, and conditioned medium was
collected for evaluation of glycosaminoglycan (GAG), prostaglandin E2 (PGE2), nitric oxide (NO), and matrix metalloproteinases-3 and -13(MMP-3, MMP-13) levels. In a second set of experiments, cartilage incubated with ADA was simultaneously exposed to the adenosine kinase
inhibitor 5′-iodotubercidin (ITU) to inhibit adenosine breakdown, or to the A2A adenosine receptor agonist N6-[2-(3,5-dimethoxyphenyl)-
ethyl]adenosine (DPMA). Finally, explants were incubated with the adenosine receptor antagonists ZM241385, CGS15943, theophylline or
caffeine to block normal receptor activation by endogenous adenosine.
Results: Exposure to ADA induced a concentration-dependent increase in GAG release and production of total MMP-3, MMP-13, PGE2, and
NO. Both ITU and DPMA inhibited the ADA-mediated increases in GAG release and PGE2, and NO production, but only ITU inhibited
MMP-13 release. Exposure to ZM 241385 increased GAG, MMP-3 and MMP-13 release. Additionally, CGS 15943 increased MMP-3
production while theophylline increased GAG, PGE2, and NO release.
Conclusions: Endogenous adenosine levels appear to regulate cartilage matrix homeostasis even in the absence of inflammation.
Regulation occurs, at least in part, through activation of cell surface receptors. This study suggests that autocrine and paracrine responses
to adenosine release are important for maintenance of healthy articular cartilage.
© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Adenosine, Adenosine Deaminase, Cartilage, Degradation.
Introduction
The purine base adenosine is a naturally occurring multi-
functional signaling molecule capable of eliciting anti-
inflammatory responses in several in vitro and in vivo
models of inflammation1–5. The therapeutic potential of
adenosine for managing inflammatory joint disease has
been investigated in previous studies documenting its
ability to limit synoviocyte6 and chondrocyte7,8 inflamma-
tory responses and to minimize articular damage in
adjuvant-induced models of arthritis in rats9–11. Although
the physiological effects of adenosine stimulation have
been studied in the presence of naturally occurring and
experimentally induced inflammation, the role of adenosine
as an autocrine or paracrine regulator of chondrocytes and
cartilage matrix homeostasis has not been investigated
previously.
Extracellular adenosine activates P1 purinergic cell sur-
face receptors that have been categorized into four sub-
classes: the A1 and A3 receptor subclasses that are
negatively coupled to adenylate cyclase and the A2A and
A2B that stimulate adenylate cyclase and increase cAMP
production12. Chondrocytes in articular cartilage are
sparsely distributed in a dense extracellular matrix and
must rely on diffusible signals in lieu of direct cell to cell
contact to communicate with one another. Recognizing
the fact that chondrocytes are capable of releasing adeno-
sine13, we hypothesized that local adenosine release from
chondrocytes could provide an important intra-articular
signal regulating cartilage homeostasis.
The availability of adenosine as an endogenous extra-
cellular signaling molecule would be regulated by its short
half-life, typically less than one minute in biological
systems13–16. Rapid phosphorylation of adenosine to form
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ATP occurs within the cell through the actions of adenosine
kinase17. Alternatively, in the extracellular space and cyto-
sol, adenosine is metabolized by enzymes including
adenosine deaminase (ADA), which irreversibly converts
adenosine to inosine (Fig. 1). Adenosine deaminase 1 is a
predominately cellular form while ADA 2 is more prevalent
in serum18–20. Elevated levels of both forms of ADA have
been reported in patients suffering from rheumatoid
arthritis21–23. Those studies suggest that a reduction in
local levels of adenosine may contribute to the synovial
inflammation associated with naturally occurring arthritic
conditions including immune mediated arthritis. The
amount of adenosine available to stimulate cell surface
receptors is dependent upon the balance between the
release, uptake and hydrolysis of extracellular adeno-
sine24. Fluctuations in the pathways that produce or con-
sume adenosine could significantly impact extracellular
adenosine concentrations and alter receptor stimulation.
The purpose of the study reported here was to investi-
gate the role of endogenous adenosine in maintaining
cartilage matrix homeostasis. This was first evaluated by
enzymatically depleting extracellular adenosine through
the addition of ADA. We then investigated whether an
adenosine kinase inhibitor, that increases local adenosine
levels, could counter the effects of ADA supplementation. In
addition, we stimulated adenosine receptors with an A2A
adenosine receptor agonist to determine if we could block
the effects of ADA exposure through receptor activation.
Finally, we used adenosine receptor antagonists to deter-
mine whether we could mimic the effects of ADA exposure
by blocking cell surface adenosine receptor activation.
The physiological impact of altered adenosine signaling
was evaluated by measuring glycosaminoglycan (GAG)




Commercial immunoassays for PGE2 and MMP-3 were
purchased from R&D Systems (Minneapolis, MN, U.S.A.)
while those for MMP-13 were from Amersham Biosciences
(Piscataway, U.S.A.). All standard chemicals and reagents
including ADA 1, DPMA, ITU, caffeine, theophylline and
CGS 15943 were obtained from Sigma-RBI (St. Louis, MO,
U.S.A.) while ZM 241385 was purchased from Tocris
(Ellisville, MO, U.S.A). Tissue culture medium, fetal calf
serum (FCS) and amphotericin B were purchased from
Gibco-BRL (Grand Island, NY, U.S.A.), while gentamicin
sulfate was obtained from Schering-Plough Animal Health
Corp (Madison, NJ, U.S.A.).
TISSUE COLLECTION
Full-thickness articular cartilage was dissected from the
metacarpophalangeal and metatarsophalangeal joints of
fresh equine cadavers, as previously described25. Cartilage
was harvested from 18 horses between the ages of 1 and 8
years that died or were euthanized for problems unrelated
to the musculoskeletal system. At the time of tissue collec-
tion, all joints appeared normal with no evidence of synovial
effusion or synovial proliferation, and the articular cartilage
was also grossly normal. Cartilage was collected under
aseptic conditions into Dulbecco’s modified Eagle’s
medium with nutrient mixture F-12 (DMEM-F12) sup-
plemented with 100 U/ml penicillin, 100 µg/ml streptomycin,
2.5 µg/ml amphotericin B, 50 µg/ml gentamicin sulfate, and
50 µg/ml ascorbate. Tissue was rinsed and transferred
to fresh DMEM-F12 medium containing the same sup-
plements as well as 5% FCS. In this report, the term control
medium refers to fresh DMEM-F12 medium with the pre-
viously mentioned supplements and 5% FCS. Cartilage
was incubated in a humidified atmosphere of 95% air/5%
CO2 at 37°C.
MONOLAYER VIABILITY ASSAY
Chondrocytes were freed from the extracellular matrix
by use of 3-step enzymatic digestion, as previously
described25. Following digestion, undigested matrix was
removed by passing the digest through a 70-µm cell
strainer. Released chondrocytes were collected by centrifu-
gation at 230 g for 6 min. Freshly isolated chondrocytes
were plated in 24-well plates at a density of 5×105 cells/
cm2. Plated chondrocytes were allowed to stabilize in
control medium for 24 h, and confluence was confirmed
prior to initiating experimental incubations. Treated
chondrocytes were then incubated for 24 h with ADA (0.5 to
2 U/ml). Following ADA exposure, the medium was dis-
carded and cells were incubated in the dark for 1 h at
37°C with 0.5 ml of 0.6 mg/ml of methyl-tetrazolium dye26.
After incubation, the dye was aspirated and cells were
solubilized by the addition of 2 ml of dimethyl sulfoxide per
well. The contents of each well were then mixed thoroughly
with 0.675 ml of Sorensen buffer (0.1 M glycine, 0.1 M NaCl
[pH 10.5]). Finally, 200 µl aliquots from each well were
Fig. 1. Adenosine metabolism and cell surface receptor sub-
classes. Extracellular adenosine can be deaminated to inosine by
ADA or can be transported into the cell and degraded by ADA or
adenosine kinase.
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transferred to a clear 96-well plate and the optical density
was measured at 570 nm using a microplate reader. All
samples and standards were assayed in triplicate.
EXPLANT CULTURE
At 24 h post-collection, 10 to 15 mm3 cartilage explants
were cut from harvested cartilage. Explants were weighed
and combined to a total wet weight of 80 to 105 mg per
replicate, and each individual replicate was stored in a
sterile polystyrene tube in 2 ml of fresh control media.
Explants were allowed to stabilize for 36 to 48 h prior to the
initiation of experimental protocols.
Cartilage was not pooled between horses, and individual
experiments used cartilage collected from a single horse to
allow within animal comparisons. Cartilage from three to
eight different horses was used to evaluate the effects of
each reagent on matrix metabolism. Explants from individ-
ual horses were exposed to experimental reagents in a
total volume of 2 ml of control medium for an incubation
period of 72-h. Each experimental treatment was per-
formed in triplicate for every horse being tested. At the
conclusion of the 72-h exposure period, aliquots of con-
ditioned medium were stored separately at −20°C so that
multiple assays could be performed. Tissue culture medium
designated for PGE2 measurement was stored at −20°C
with 10 µg/ml of the prostaglandin synthetase inhibitor
indomethican.
EXPERIMENTAL DESIGN
In the first part of the study, cartilage explants were
exposed to ADA (0.5 to 2 U/ml) to deplete endogenously
released adenosine. In addition, control explants were
treated with heat-denatured ADA (95°C for 15 min) to verify
that the observed effects of ADA exposure were due to
enzymatic activity and not to impurities. Finally, explants
were exposed to inosine (1 to 100 µM) to evaluate whether
products of adenosine metabolism could be responsible for
the effects that were observed.
The next part of the study was designed to confirm
whether the observed effects of ADA exposure were
adenosine-dependent. We first evaluated whether we could
limit the effects of ADA by inhibiting other pathways
of adenosine degradation. Explants were incubated with
the adenosine kinase inhibitor 5′-iodotubercidin (ITU;
0.1 to 1 µM) in the presence of 2 U/ml ADA. Another
set of explants was incubated with the ADA-resistant A2A
specific receptor agonist N6-[2-(3,5-dimethoxyphenyl)-
ethyl]adenosine (DPMA; 0.1 to 10 µM) in the presence of
2 U/ml ADA to determine whether the effects of ADA
exposure could be reversed by direct adenosine receptor
stimulation. Finally, cartilage explants were exposed to one
of the following adenosine receptor antagonists to deter-
mine whether direct inhibition of adenosine receptor acti-
vation could mimic ADA-induced responses: the A2A
specific antagonist ZM 241385 (1 µM), the broad antagon-
ist CGS 15943 (1 µM), the broad receptor antagonist caf-
feine (1 mM), or the broad receptor antagonist theophylline
(1 mM).
PROTEOGLYCAN ASSAY
Proteoglycan release was estimated by measuring the
concentration of GAG released into the experimental
medium using the 1,9-dimethylmethylene blue (DMMB),
metachromatic dye assay modified for use in microtiter
plates25. Shark chondroitin sulfate was used as the stan-
dard. Briefly, 10 µl aliquots of medium and standards were
pipetted onto a 96-well plate and mixed with 200 µl of 20 µg
DMMB/ml (pH 3.3). Optical density was measured at a
wavelength of 540 nm with a reference wavelength of
595 nm. All samples and standards were assayed in tripli-
cate and GAG concentration was normalized to µg GAG
per mg wet weight.
PGE2 ASSAY
The concentration of PGE2 was measured using a com-
mercially available competitive enzyme immunoassay.
Briefly, medium was diluted 100 fold in DMEM-F12 and
aliquots of diluted sample or standard were added to each
well of a microplate that was coated with polyclonal anti-
mouse antibody. Subsequently, PGE2 conjugated to alka-
line phosphatase and a monoclonal antibody to PGE2 were
added to each well and the plate was incubated for 2 h.
Following incubation, the plate was washed and substrate
solution was added to each well. Following a 1-h incubation
phosphoric acid was added to each well and optical density
was measured at 405 nm with a reference of 570 nm. All
samples and standards were assayed in duplicate and
PGE2 production was normalized per mg wet weight.
NO ASSAY
Nitric oxide production by chondrocytes can be accu-
rately estimated by measuring the concentration of nitrite in
a conditioned medium sample27,28. Nitrite levels were
measured using a spectrophotometric assay based on the
Greiss reaction29. To measure nitrite, 200 µl samples of
conditioned medium or standards were mixed with of
fresh Greiss reagent centrifuged at 4600 g for 4 min. After
centrifugation, samples were transferred to a 96-well plate
and the optical density was measured at 570 nm using a
microplate reader. All samples and standards were
assayed in triplicate and NO production was normalized
per mg wet weight.
MMP-3 ASSAY
Concentration of total MMP-3 in medium was measured
using a commercially available solid phase immunoassay.
Conditioned medium samples were diluted 10-fold in poly-
propylene tubes and diluted samples or standards were
added with the supplied buffer to wells of a microplate
coated with polyclonal anti-MMP-3 antibody. Following a
2-h incubation, the plate was washed and anti-MMP-3
antibody conjugated to horseradish peroxidase was added
to each well. After a subsequent 2-h incubation, the plate
was washed and substrate solution was added to each
well. The microplate was incubated for an additional 30 min
before sulfuric acid was added to each well and optical
density was measured at 450 nm with a reference of
570 nm. All samples and standards were assayed in dupli-
cate and MMP-3 production was normalized per mg wet
weight.
MMP-13 ASSAY
Concentrations of MMP-13 in medium samples were
measured using a commercially available solid phase
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immunoassay. Briefly, aliquots of undiluted sample or stan-
dard were added to a microplate coated with anti-MMP-13
antibody and incubated for 2 h. The plate was subsequently
washed and anti-MMP-13 antibody conjugated to horse-
radish peroxidase was added to each well for 1 h before
substrate solution was added to each well. After the plate
was incubated for another 30 min, sulfuric acid was added
to each well and optical density was measured at 450 nm.
All samples and standards were assayed in duplicate and
MMP-13 production was normalized per mg wet weight.
STATISTICAL ANALYSIS
All values are expressed as mean±SEM. Combined data
from all horses were analyzed by use of an ANOVA. When
the ANOVA indicated significance, post hoc means com-
parisons were performed to determine significant differ-
ences between individual groups. For experiments in which
reagents were added individually, the differences between
control measurements and treatment measurements were
evaluated using a Dunnett’s test (P<0.05). Alternatively, for
experiments in which mediators were added alone and in
combination, comparisons between data pairs were per-
formed by use of the Student t-test (P<0.05). All analysis
was performed using the SAS 8™ statistical software
package (SAS Institute, Cary, NC, U.S.A.).
Results
EXPOSURE TO ADA DID NOT SIGNIFICANTLY AFFECT
CHONDROCYTE VIABILITY
Chondrocytes in monolayer were exposed to ADA (0.5 to
2 U/ml) in order to determine the effect of ADA on chondro-
cyte viability. Exposure to ADA did not significantly affect
the viability of chondrocytes (Fig. 2).
DEPLETION OF ENDOGENOUS ADENOSINE THROUGH EXPOSURE
TO ADA RESULTED IN CARTILAGE MATRIX DEGRADATION, MMP,
PGE2, AND NO RELEASE
Cartilage explants were exposed to ADA (0.5 to 2 U/ml)
in order to determine the effects of depleting endogenously
produced adenosine on the regulation of cartilage matrix
homeostasis. Explants cultured in the presence of ADA
released significantly higher levels of GAG into the con-
ditioned medium, indicating enhanced degradation of
matrix proteoglycan (Fig. 3A). Similarly, exposure to ADA
resulted in a concentration-dependent increase in the syn-
thesis of PGE2 (Fig. 3B) and NO release (Fig. 3C). Finally,
cartilage exposed to ADA produced higher amounts of total
MMP-3 (Fig. 3D) and MMP-13 (Fig. 3E). Exposure to
heat-denatured ADA did not increase GAG, NO or PGE2
release when compared to explants cultured in control
tissue culture medium alone. Similarly, explants incubated
with inosine (1 to 100 µM), a product of adenosine break-
down by ADA, did not increase release of GAG, NO or
PGE2.
AN ADENOSINE KINASE INHIBITOR LIMITED THE EFFECTS OF ADA
EXPOSURE
Cartilage explants exposed to ADA (2 U/ml) were co-
incubated with the adenosine kinase inhibitor ITU (0.1 to
1 µM) in order to determine whether reducing the enzy-
matic utilization of adenosine could counteract the effects
of ADA exposure. Incubation with ITU (0.2 to 1 µM) signifi-
cantly decreased GAG (Fig. 4A) and PGE2 (Fig. 4B)
release from ADA-exposed cartilage explants, to the extent
that co-addition of 0.5 or 1 µM ITU resulted in GAG and
PGE2 levels that were not significantly higher than release
from control tissue. Similarly, incubation with ITU (0.2
to 1 µM) decreased NO production from ADA-exposed
explants in a concentration-dependent manner (Fig. 4C)
with NO release returning to control levels at 1 µM ITU. In
contrast, co-incubation with ADA and ITU at these concen-
trations did not effectively inhibit ADA-mediated increases
in total MMP-3 production (Fig. 4D). Higher concentrations
of ITU (0.5 and 1 µM) did, however, reduce ADA-induced
MMP-13 to levels that were not significantly different from
control explants (Fig. 4E). Exposure to ITU (0.1 to 1 µM) in
the absence of ADA did not significantly alter GAG release,
PGE2 synthesis, NO production, total MMP-3 or MMP-13
production when compared to explants cultured in control
tissue culture medium alone.
AN A2A ADENOSINE RECEPTOR AGONIST LIMITED THE EFFECTS
OF ADA EXPOSURE
Cartilage explants exposed to ADA (2 U/ml) were incu-
bated with the A2A agonist DPMA (0.1 to 10 µM) to deter-
mine whether direct adenosine receptor stimulation could
reverse the adverse effects of ADA exposure. Incubation
with DPMA significantly reduced GAG release (Fig. 5A) and
PGE2 production (Fig. 5B) from cartilage explants stimu-
lated with ADA. Similarly, incubation with DPMA (1 to
10 µM) decreased ADA-induced NO production (Fig. 5C).
In the presence of both ADA and DPMA, glycosaminogly-
can, NO and PGE2 levels remained significantly higher
than levels produced by control cartilage at all concen-
trations of DPMA tested. In addition, exposure to DPMA did
not alter the ADA-induced increase in total MMP-3 (Fig. 5D)
or MMP-13 levels (Fig. 5E). Exposure to DPMA (0.1 to
10 µM) in the absence of ADA did not significantly alter
GAG release, PGE2 synthesis, NO production, total MMP-3
or MMP-13 production relative to levels detected from
explants cultured in control tissue culture medium alone.
BLOCKING RECEPTOR ACTIVATION WITH ADENOSINE RECEPTOR
ANTAGONISTS ALTERED CARTILAGE MATRIX DEGRADATION AS
WELL AS MMP, PGE2, AND NO RELEASE
Cartilage explants were incubated with different adeno-
sine receptor antagonists in order to evaluate whether
Fig. 2. Effect of ADA exposure on articular chondrocyte viability.
Equine chondrocytes were exposed to 0.5 to 2 U/ml ADA for
24 h. ADA did not reduce chondrocyte viability. Values reported
represent mean±SEM.
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adenosine receptor inhibition would also affect cartilage
homeostasis. Exposure to ZM 241385 increased GAG
release, total MMP-3, and MMP-13 levels but did not
significantly alter PGE2 or NO production (Table I).
Exposure to CGS 15943 increased GAG release and total
MMP-3 levels but did not significantly affect PGE2, NO or
MMP-13 production. Incubation with theophylline resulted
in an increase in GAG, PGE2 and NO release but did not
significantly change the production of either MMP-3 or
MMP-13. In contrast, exposure to caffeine did not signifi-
cantly alter GAG release, PGE2 synthesis, NO production,
or total MMP-3 and MMP-13 levels compared to explants
cultured in control medium alone.
Discussion
The ability of exogenously supplied adenosine to attenu-
ate intraarticular inflammatory responses and limit associ-
ated tissue damage in the joint has been documented
previously6,9–11. The potential significance of this obser-
vation is enhanced by recent clinical observations regard-
ing elevated ADA activity measured in patients with
naturally occurring arthritic conditions. Increased ADA
activity has been documented in the synovial fluid22,23 and
synovial fibroblasts22 of RA patients and in the serum of
patients suffering from RA and systemic lupus erythemato-
sus22,22,30, and ADA levels correlate well with disease
activity in RA30. Furthermore, the widely used and highly
effective anti-rheumatic drug methotrexate (MTX) has been
shown to increase concentrations of extracellular adeno-
sine31,32 and decrease ADA activity in vivo33. Based on
these studies indicating that a reduction in local concen-
trations of adenosine may play a significant role in the
pathophysiology of naturally occurring joint disease22,34,35,
we theorized that depletion of endogenously released
adenosine would be detrimental to cartilage matrix homeo-
stasis in the absence of other mediators of disease.
Fig. 3. Effects of ADA-induced adenosine depletion on articular cartilage explant homeostasis. Equine articular cartilage was cultured with
0.5 to 2 U/ml ADA for 72 h. Cartilage exposed to ADA showed a dose-dependent increase in (A) GAG release (N=8), (B) PGE2 synthesis(N=8), (C) NO production (N=8), (D) total MMP-3 levels (N=6), and (E) MMP-13 (N=3). Values reported represent mean±SEM. *Value is
significantly higher than control levels measured in the absence of ADA (P<0.05).
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The two major enzymatic pathways that utilize adenosine
are phosphorylation by adenosine kinase and deamination
by ADA19. In this study ADA activity was used to deplete
adenosine levels to test our hypothesis. We selected
ADA because it has been shown to exist in an extracellular
form in vivo20 while adenosine kinase is primarily active
in the cytosol36. Several isoenzymes of ADA, both free
and bound to CD26, with differing molecular weights,
kinetic properties and tissue distributions, have been
described22,37. Adenosine deaminase 1 was chosen for
this study because it has a higher affinity for adenosine and
a higher catalytic activity with deoxyadenosine22,38. In
addition, in normal and disease states where elevated
ADA activity has been detected, the ADA 1 isozyme has
predominated in human tissues and cells19,20,22.
The concentrations of ADA utilized in this study were
higher those measured in the serum (0.0393 U/ml)30 or
synovial fluid (0.0144 U/ml)22 of RA patients or in serum
samples from normal healthy controls (0.0157 U/ml)30.
However, viability-testing results reported here show
that the concentrations of ADA used in this study do
not adversely affect chondrocyte viability. Pilot studies
performed using up to 8 U/ml ADA indicated that
concentration-dependent responses were observed in the
range between 0.5 and 2 U/ml ADA while above 2 U/ml
cartilage responses plateaued. In vivo, cells have the ability
to continually synthesize and replace ADA as the protein
becomes inactivated, but in this experimental model
ADA was added to the culture system only once, at
the initiation of experiments. The upper limit of the
Fig. 4. Effects of adenosine kinase inhibition on ADA-exposed cartilage explants. Equine articular cartilage explants were cultured with
2 U/ml ADA and exposed to 0.1 to 1 µM of the adenosine kinase inhibitor ITU for 72 h. Cartilage exposed to ITU showed a dose-dependent
decrease in ADA-mediated (A) GAG release (N=5), (B) PGE2 synthesis (N=5), and (C) NO production (N=5). Incubation with ITU did not
significantly reduce (D) total MMP-3 levels (N=4) but did inhibit ADA-induced (E) MMP-13 production (N=3). Values reported represent
mean±SEM. T Value is significantly higher than control levels measured in the absence of ADA (P<0.05). *Value is significantly lower than
2 U/ml ADA alone (P<0.05).
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concentration-dependent range (2 U/ml) was selected for
use in these experiments to ensure enzymatic degradation
of endogenous adenosine for the entire 72-h incubation
period.
In designing this study, we presumed that cartilage
responses to ADA exposure would be due to decreased
concentrations of extracellular adenosine. However, we
did recognize that ADA supplementation could affect
explant homeostasis through other mechanisms, including
exposure to products of adenosine degradation. Cartilage
exposed to inosine, the product of adenosine breakdown
by ADA, did not increase matrix degradation or second
messenger release, suggesting that inosine did not play an
important role in the observed effects of ADA exposure in
this study. Cartilage explants were also exposed to heat-
denatured ADA to test for potential contamination of the
enzyme preparation with endotoxin. Heat treatment to
denature ADA under conditions under which lipopoly-
saccharide was not expected to be adversely affected39
abolished ADA-induced release of GAG, NO and PGE2,
demonstrating that endotoxin contamination was not
responsible for the effects of ADA exposure observed in
this study.
This study included several additional experiments
designed to confirm that ADA was acting via adenosine
depletion. Previous work demonstrated that ITU causes
chondrocytes to accumulate high concentrations of extra-
cellular adenosine12. The ability of ITU to increase extra-
cellular adenosine is most likely due to enzyme kinase
inhibition, although ITU has been demonstrated to inhibit
nucleoside transport with a Ki higher than the concen-
trations of ITU utilized in this study40. In this study, co-
exposure of cartilage to ITU inhibited ADA-induced effects
in a concentration-dependent manner, indicating that ITU
may be directly antagonizing the ability of ADA to reduce
the concentration of extracellular adenosine. Similar results
were obtained following co-incubation with ADA and the
A2A specific agonist DPMA. Receptor agonists including
DPMA, signal through cell surface receptors, mimicking the
effects of extracellular adenosine7 and chondrocytes have
been shown to possess transcripts for P1 receptors41. The
ability of DPMA to modulate cartilage responses to ADA
exposure suggests that in addition to promoting anti-
inflammatory responses7,8,10,42,43, adenosine receptors, in
particular A2A, may also be important in delivering signals
that instruct chondrocytes to maintain cartilage matrix.
Together, these results provide good evidence that the
observed effects of ADA exposure were mediated by
reduced adenosine concentrations.
Adenosine deaminase can bind to A1 and the low affinity
A2B adenosine receptors and increase receptor ligand
affinity44–47, which suggests an alternative role for ADA in
this study. However, the significance of this phenomenon
for interpretation of the current study is difficult to assess.
The original experiments demonstrating ADA receptor bind-
ing were performed using a cell line with admittedly high
expression levels of A1 receptor44,45. In addition, exper-
iments demonstrating an increased ligand receptor affinity
in the presence of ADA used a synthetic receptor agonist.
Chondrocytes exposed to ADA alone in this study would
only have adenosine available as an agonist and an
evaluation of the ability of adenosine to bind cell surface
receptors before being degraded by ADA is beyond the
scope of this study. It is unlikely that the effects of ADA
exposure observed in this study are due to ADA-mediated
increases in A2B binding as previous work has demon-
strated that Gs stimulation and increased cAMP are linked
to decreased NO release7, which is opposed to results
reported in this study. Finally, the A1 and A2 subclasses
of adenosine receptors produce antagonizing effects on
adenylyl cyclase and cAMP production and the net effect of
ADA-enhanced receptor binding would be dependent upon
which receptor was present in greater numbers.
The last section of the study reported here was designed
to reproduce ADA-like responses indirectly, without
decreasing extracellular adenosine by using adenosine
receptor antagonists to block receptor stimulation by
endogenous adenosine. The conclusion that A2A receptors
play a role in regulating matrix homeostasis was supported
by the ability of the A2A specific antagonist ZM 241385 to
mimic the effects of ADA exposure and increase GAG
release and MMP levels. Although exposure to the A2A
specific antagonist ZM 241385 increased cartilage cata-
bolic activity, not all of the receptor antagonists used in this
study caused measurable responses. These results are
similar to those reported in another study is which exposure
to caffeine or theophylline alone had no effect in an in vivo
rat adjuvant arthritis model of RA34. Furthermore, unstimu-
lated chondrocytes accumulate only low levels of extra-
cellular adenosine13 and it is possible that lower affinity
antagonists may not be able to block enough of the low,
tonic receptor stimulation to see changes in cartilage
homeostasis. In addition to blocking adenosine receptors,
theophylline is known to be a phosphodiesterase inhibitor48
and the observed changes in cartilage metabolism may be
due to inadvertent effects of the reagent.
Chondrocytes have been shown to release adenosine
in response to inflammatory stimuli13, and endogenous
adenosine may provide a negative feedback loop to
limit cartilage damage after the initiation of inflammatory
responses14. This suggests that enzymes other than ADA
that affect the concentration of extracellular adenosine may
Table I
Effects of adenosine receptor antagonists on articular cartilage explants. Equine articular cartilage was cultured for 72 h alone (control) or
with one of the following adenosine receptor antagonists: 1 µM of the A2A specific antagonist ZM 241385, 1 µM of the broad antagonist CGS
15943, 1 mM of the broad antagonist theophylline or 1 mM of the broad antagonist caffeine. Cartilage incubated with ZM 241385 increased
GAG release and total MMP-3 and MMP-13 levels while exposure to CGS 15943 increased MMP-3 alone. Theophylline exposure caused
an increase in GAG release, PGE2 synthesis and NO production. Values reported represent mean±SEM










Control 2.39±0.29 417±119 0.83±0.43 2.51±0.56 0.67±0.27
1 µM ZM 241385 3.70±0.50* 380±104 0.56±0.26 4.83±0.28* 1.73±0.07*
1 µM CGS 15943 3.46±0.07 364±113 0±0 4.56±0.35* 0.3±0.17
1 mM Theophylline 3.67±0.35* 1761±381* 2.2±0.22* 2.78±0.71 0.53±0.39
1 mM Caffeine 2.46±0.28 464±135 0±0 2.73±0.51 0.73±0.03
*Value is significantly higher than control levels measured in the absence of ADA (P<0.05).
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also be capable of modulating cartilage homeostasis. In
support of this, increased activity of the key49 adenosine
generating enzyme 5′ nucleotidase (5NT) has been found
in diseased cartilage50, suggesting that 5NT may be up-
regulated in response to disease. Further investigation into
the relationship between 5NT, extracellular adenosine
levels and cartilage homeostasis is certainly warranted. In
the current study GAG release was measured as an
indicator of proteoglycan degradation, and production
of MMP-3 (stromelysin-1) and MMP-13 (collagenase-3)
were quantified as markers of matrix degradative activity51.
Stromelysin-1, which was increased by exposure to ADA,
has been found in synovial fluid samples from patients with
a variety of pathologic conditions including RA52 and has
also been show to activate a variety of other catabolic
enzymes53. Collagenase-3, which was also increased with
exposure to ADA, is thought to be a key mediator in OA
associated with chondrocyte mediated cartilage destruc-
tion54, and may be the primary collagenase responsible for
matrix degradation in OA cartilage55.
Although ADA and an A2A-selective receptor antagonist
both initiated an increase in MMP production, the control of
MMP expression may not be entirely adenosine-
dependent. The A2A agonist DPMA was unable to inhibit
ADA-induced MMP-3 or MMP-13 expression. Similarly,
incubation with ITU did not inhibit MMP-3 production
in response to ADA. The inability of both receptor-
dependent and receptor-independent adenosine modu-
lation to inhibit ADA-induced increases in MMP-3 levels
suggests that, once production is initiated, the mechanism
Fig. 5. Effects of selective A2A adenosine receptor stimulation on ADA-exposed cartilage explants. Equine articular cartilage was cultured
with 2 U/ml ADA and exposed to 0.1 to 10 µM of the A2A receptor agonist DPMA for 72 h. Incubation with DPMA inhibited ADA-induced (A)
GAG release (N=5), (B) PGE2 synthesis (N=5), and (C) NO production (N=5) but did not decrease (D) total MMP-3 levels (N=4), or (E)
MMP-13 (N=3). Values reported represent mean±SEM. T Value is significantly higher than control levels measured in the absence of ADA
(P<0.05). *Value is significantly lower than 2 U/ml ADA alone (P<0.05).
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of down-regulating these enzymes may be complex and
should be the focus of further study.
This study reveals that endogenously released adeno-
sine can regulate chondrocyte production of matrix degrad-
ing enzymes and matrix loss. In a previous study
measuring adenosine release from articular chondrocytes
cultured in monolayer, no adenosine was detected in con-
ditioned medium from unstimulated cells13. However, it is
likely that adenosine levels below the sensitivity threshold
of the assay (<100 nM) were present in the medium and
that those levels would be sufficient to result in intracellular
signaling. In addition, higher levels of adenosine could be
expected to be present at the cell surface. Alternatively,
considering the extremely short half-life of adenosine in
biological systems14–16, higher levels of adenosine may
have been release by unstimulated cells in that study, but
have been naturally degraded to levels below the detection
threshold prior to completion of the high performance liquid
chromatography assay.
Studies of naturally occurring joint pathology have
suggested that local adenosine levels are important in
disease and in vitro work has indicated that adenosine
modulates chondrocyte responses to inflammatory stimuli.
The purpose of this study was to investigate the potential of
endogenous adenosine as an autocrine and paracrine
regulator of articular chondrocytes. The long-term goal of
adenosine research is to develop an agent that can limit
joint damage that occurs with injury or disease. Release of
adenosine from chondrocytes appears to play a role in the
cellular response to tissue damage in arthritic conditions,
and pharmacologic modulation of these pathways in joints
may have therapeutic potential. This study demonstrates
that endogenous adenosine affects cartilage matrix
integrity in the absence of inflammatory stimuli and
strengthens the hypothesis that adenosine is a powerful
signaling agent in the joint.
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